Tricor (fenofibrate) is a prescription medication specifically formulated to address dyslipidemia, a critical factor in cardiovascular disease risk. As a member of the fibrate class, it operates by modulating key enzymes and receptors involved in lipid metabolism, leading to significant improvements in atherogenic lipid profiles. Its primary mechanism focuses on activating peroxisome proliferator-activated receptor alpha (PPARα), which governs the expression of genes responsible for lipid breakdown and clearance. This targeted action makes Tricor a cornerstone therapy for patients who require focused management of high triglycerides and low HDL-C, particularly when statin therapy alone is insufficient or not optimally tolerated. By directly targeting these lipid abnormalities, Tricor plays a vital role in a comprehensive strategy to reduce the long-term risk of pancreatitis and atherosclerotic cardiovascular events.

Features

• Active pharmaceutical ingredient: Fenofibrate (micronized or nanoparticle formulations for enhanced bioavailability)
• Available in multiple strengths: 48 mg and 145 mg tablets
• PPARα agonist with high specificity for lipid-regulating pathways
• Demonstrated efficacy in reducing triglyceride levels by up to 50% in clinical studies
• Significant HDL-C elevation, often in the range of 10-20%
• Modest LDL-C reduction, with a more pronounced effect on shifting LDL particle size to a less atherogenic phenotype
• Convenient once-daily dosing regimen
• Manufactured under strict cGMP (current Good Manufacturing Practices) standards

Benefits

• Substantial Reduction in Pancreatitis Risk: By effectively lowering severely elevated triglyceride levels (often above 500 mg/dL), Tricor directly reduces the risk of acute pancreatitis, a serious and painful complication of hypertriglyceridemia.
• Improved Cardiovascular Risk Profile: Through its dual action of lowering triglycerides and raising HDL-C, Tricor modifies the lipid triad associated with metabolic syndrome, contributing to an overall improved atherogenic index and long-term cardiovascular outlook.
• Targeted Therapy for Mixed Dyslipidemia: Provides a specialized treatment option for patients whose lipid abnormalities are not fully addressed by statins alone, particularly those with persistently high triglycerides and low HDL despite LDL control.
• Favorable Safety and Tolerability Profile: Extensive clinical use and post-marketing surveillance have established a well-characterized safety profile, with most adverse effects being mild and transient when used as directed under medical supervision.
• Synergy in Combination Therapy: When combined with a statin under careful physician guidance, it can provide comprehensive lipid management, addressing multiple lipid parameters simultaneously for high-risk patients.
• Positive Impact on Lipoprotein Subclasses: Promotes a shift from small, dense LDL particles (highly atherogenic) to larger, buoyant LDL particles, and favorably alters other lipoprotein subfractions involved in atherosclerosis.

Common use

Tricor is primarily indicated as an adjunct to diet for the treatment of adults with severe hypertriglyceridemia. It is also used to treat primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Type IIa and IIb) in patients who have not achieved target lipid levels with other lipid-lowering agents or for whom such agents are not suitable. Its use is common in patients with type 2 diabetes who often present with the characteristic dyslipidemia of high triglycerides and low HDL cholesterol. It is frequently incorporated into the management plans for patients with metabolic syndrome.

Dosage and direction

The dosage of Tricor must be individualized based on patient response and tolerability. The usual recommended dose for adults is 145 mg taken once daily. For some patients, particularly the elderly or those with renal impairment, a lower initial dose of 48 mg daily may be prescribed. The tablet should be swallowed whole with a full glass of water and can be taken with or without food, though consistency in administration with respect to meals is recommended. Therapy should always be initiated alongside a appropriate lipid-lowering diet, which should be continued during treatment. Liver function tests and lipid levels should be monitored periodically to determine patient response and to inform any necessary dosage adjustments.

Precautions

Prior to initiating Tricor therapy, a thorough clinical assessment is necessary. This should include measurement of baseline serum triglycerides and cholesterol levels, liver function tests (transaminases), creatinine, and creatine phosphokinase. Use with caution in patients with a history of liver disease, gallbladder disease, or hypothyroidism. Pancreatitis has been reported in patients taking Tricor; therefore, if abdominal pain or other symptoms suggestive of pancreatitis occur, discontinue use and investigate promptly. Muscle toxicity, including myositis and rhabdomyolysis, can occur, with risk increased in patients with renal impairment, diabetes, or hypothyroidism. Periodic eye examinations are recommended as fenofibrate may cause cataract formation. Alcohol consumption should be minimized due to its potential to increase triglyceride levels and its additive effect on the liver.

Contraindications

Tricor is contraindicated in patients with hypersensitivity to fenofibrate or any component of the formulation. It must not be used in patients with severe renal impairment, including those on dialysis. It is contraindicated in patients with active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities. It is also contraindicated in patients with pre-existing gallbladder disease. Use in pediatric patients and during breastfeeding is contraindicated due to a lack of sufficient safety data.

Possible side effect

The most common side effects associated with Tricor are generally mild and may include respiratory disorders, headache, back pain, and nausea. More significant adverse reactions can occur and may include:

• Hepatic: Increases in liver enzymes (AST, ALT), hepatitis, cirrhosis
• Musculoskeletal: Myalgia (muscle pain), arthralgia, rhabdomyolysis (rare but serious)
• Gastrointestinal: Abdominal pain, constipation, diarrhea, nausea, cholelithiasis (gallstones)
• Dermatological: Rash, photosensitivity reactions, urticaria
• Cardiovascular: Deep vein thrombosis, pulmonary embolism
• Ophthalmic: Cataracts, blurred vision
• Hematologic: Anemia, leukopenia, thrombocytopenia Patients should be advised to report any unusual muscle pain, tenderness, weakness (especially if accompanied by fever or malaise), yellowing of skin or eyes, or severe abdominal pain immediately.

Drug interaction

Tricor has the potential for several clinically significant drug interactions. It may potentiate the effects of oral anticoagulants (e.g., warfarin), requiring more frequent monitoring of prothrombin time/INR and possible adjustment of the anticoagulant dose. Concomitant administration with other fibrates or statins (e.g., atorvastatin, simvastatin) increases the risk of myopathy or rhabdomyolysis; this combination should generally be avoided unless the potential benefit outweighs the risk and the patient is closely monitored. Bile acid sequestrants (e.g., cholestyramine) may bind to Tricor and reduce its absorption; these medications should be taken at least 1 hour before or 4-6 hours after Tricor. Cyclosporine can increase Tricor exposure and should be used with caution. Tricor may increase the serum concentration of some immunosuppressants.

Missed dose

If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should not take a double dose to make up for a missed one. Maintaining a consistent daily schedule is important for optimal therapeutic effect.

Overdose

There is no specific antidote for fenofibrate overdose. Treatment should be supportive and symptomatic. In the event of a suspected overdose, contact a poison control center or emergency medical services immediately. Given its high protein binding, fenofibrate is not expected to be significantly dialyzable. Management should focus on monitoring vital signs and providing general supportive care, with particular attention to possible hepatic and muscular effects.

Storage

Store Tricor tablets at room temperature, between 20°C to 25°C (68°F to 77°F), in a dry place. Excursions are permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original container, tightly closed, and out of reach of children and pets. Do not store in bathrooms or other areas with high humidity. Properly discard any unused medication after the expiration date or when no longer needed.

Disclaimer

This information is provided for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the manufacturer’s prescribing information but may not be exhaustive. Individual patient responses to medication can vary.

Reviews

“After struggling with persistently high triglycerides despite being on a statin, my cardiologist added Tricor 145 mg. Within three months, my triglycerides dropped from 450 to 150 mg/dL. The once-daily dosing is convenient, and I’ve experienced no side effects. It has been a crucial part of getting my lipid numbers to goal.” — Michael R., 58

“As an endocrinologist, I frequently prescribe Tricor for my diabetic patients with significant hypertriglyceridemia. Its efficacy in lowering triglycerides is consistently impressive, and it often provides a beneficial boost to HDL levels. I appreciate that it offers a targeted approach for this specific lipid abnormality within a comprehensive diabetes management plan.” — Dr. Eleanor S., MD

“I was initially concerned about adding another medication, but my doctor explained the risk of pancreatitis with my very high triglycerides. I’ve been on Tricor for over a year now. My triglycerides are now well within normal limits, and I feel reassured that I’m reducing a significant health risk. The peace of mind is worth it.” — Sarah K., 45